29/02/2020
illness
07/02/2020
Ravulizumab (Ultomiris®) with no added benefit
The Federal Joint Committee (G-BA) has certified that the second C5 complement inhibitor ravulizumab (Ultomiris®) approved against paroxysmal nocturnal hemoglobinuria (PNH) has no additional benefit compared to the appropriate comparator therapy (previous standard) eculizumab (Soliris®). This resulted in the benefit assessment procedure according to Section 35a SGB V, which was completed on February 6, 2020. READ MORE
03/01/2020
Survey on working conditions
The University of Cologne - Chair for Work and Vocational Rehabilitation - would like to find out in an anonymous online survey what the working conditions of people with health impairments are like. The aim is to use the information obtained "at first hand" to help improve their working conditions in the long term. Anyone over the age of 18 who is currentlyREAD MORE
23/12/2019
Big donation from the JAV of the BVG
Donation handover at the JAV of the BVG
06/12/2019
DGHO guideline on PNH updated
The German Society for Hematology and Medical Oncology (DGHO) has updated the guideline for PNH . The recommendations for diagnosis and therapy were brought up to date.Loading new posts...
No more posts
